Claims Understanding weight trends, clinical indications for AOMs, remaining comorbidities, and any treatment side effects are all important factors to consider as part of claims management practices
It happens when you think your current injection is not working for you
The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear
Your provider should check on your progress regularly
In addition, changes in food intake and 24-hour urine sodium excretion were not assessed, meaning the contribution of dietary modifications including salt intake or other changes that may help to reduce blood pressure are unknown and cannot be estimated
Patients using PPIs had an increase in hospitalizations compared to non-PPI users (15% and 8% p = 0.007) (Lu et al
